OpenLB
Open Library of Bioscience
Advanced Search
Epigenomics
Mar 13, 2024;

Construction of a prognostic model based on genome-wide methylation analysis of miRNAs for hepatocellular carcinoma.

Zhaoqi Shi, Xiaolong Liu, Duguang Li, Xiaoxiao Fan, Lifeng He, Daizhan Zhou, Hui Lin
Author Information
  1. Zhaoqi Shi: Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310000, China.
  2. Xiaolong Liu: Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310000, China.
  3. Duguang Li: Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310000, China.
  4. Xiaoxiao Fan: Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310000, China.
  5. Lifeng He: Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310000, China.
  6. Daizhan Zhou: Life Science Research Center, The First Affiliated Hospital of Xinxiang Medical University, Weihui, 453100, Henan, China.
  7. Hui Lin: Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310000, China. ORCID
PMID: 38477016 DOI: 10.2217/epi-2023-0365

Abstract

Using the methylation level of miRNA genes to develop a prognostic model for patients with hepatocellular carcinoma (HCC). least absolute shrinkage and selection operator and multivariate Cox regression analyses were performed to develop a prognostic model. One miRNA in the model was selected for verification. A prognostic model was developed using eight miRNAs. The areas under the curve for predicting overall survival at 1, 3 and 5 years were 0.75, 0.81 and 0.81. miR-223 was found to be hypomethylated in 160 HCC tissues, and its methylation level was associated with Barcelona Clinic Liver Cancer stages and the prognosis of patients with HCC. The prognostic model based on miRNA methylation levels has the capability to partially forecast the prognosis of patients with HCC.

Keywords

hepatocellular carcinoma methylation miR-223 miRNA prognostic model

References

  1. Biosens Bioelectron. 2024 Jan 15;244:115810 [PMID: 37924654]
  2. Front Pharmacol. 2023 Aug 08;14:1167418 [PMID: 37614318]
  3. Curr Pharm Des. 2013;19(7):1192-200 [PMID: 23092339]
  4. Research (Wash D C). 2020 Mar 2;2020:1091605 [PMID: 32342044]
  5. J Cell Physiol. 2019 Jul;234(7):11942-11950 [PMID: 30536816]
  6. Mol Med Rep. 2018 Feb;17(2):2211-2228 [PMID: 29207133]
  7. Cell. 2009 Jan 23;136(2):215-33 [PMID: 19167326]
  8. Expert Rev Mol Diagn. 2014 Jul;14(6):673-83 [PMID: 24914586]
  9. Oncol Rep. 2019 Feb;41(2):1231-1237 [PMID: 30535501]
  10. Nat Rev Genet. 2023 Dec;24(12):816-833 [PMID: 37380761]
  11. Med Res Rev. 2020 Sep;40(5):1973-2018 [PMID: 32525219]
  12. Front Oncol. 2020 Jul 28;10:1271 [PMID: 32850386]
  13. J Transl Med. 2016 May 05;14(1):122 [PMID: 27150195]
  14. Nature. 2001 Jan 18;409(6818):363-6 [PMID: 11201747]
  15. Biosens Bioelectron. 2023 Oct 15;238:115587 [PMID: 37586263]
  16. EMBO J. 2002 Sep 2;21(17):4663-70 [PMID: 12198168]
  17. Epigenetics. 2023 Dec;18(1):2214392 [PMID: 37216580]
  18. Cancers (Basel). 2020 Oct 11;12(10): [PMID: 33050637]
  19. Biochem Biophys Res Commun. 2017 Jan 29;483(1):630-637 [PMID: 27998765]
  20. Neural Netw. 2019 Oct;118:1-16 [PMID: 31228720]
  21. Epigenomics. 2016 Mar;8(3):389-99 [PMID: 26673039]
  22. Front Bioeng Biotechnol. 2022 May 10;10:849756 [PMID: 35620469]
  23. Eur J Cancer. 2023 Sep;191:112960 [PMID: 37473464]
  24. Stat Med. 2013 Dec 30;32(30):5381-97 [PMID: 24027076]
  25. Clin Trials. 2020 Jun;17(3):285-294 [PMID: 32063031]
  26. Front Immunol. 2022 Jun 27;13:918140 [PMID: 35833147]
  27. Adv Drug Deliv Rev. 2015 Jan;81:62-74 [PMID: 25450260]
  28. EBioMedicine. 2024 Feb;100:104956 [PMID: 38199042]
  29. Clin Epigenetics. 2022 Nov 28;14(1):154 [PMID: 36443876]
  30. Philos Trans A Math Phys Eng Sci. 2016 Apr 13;374(2065):20150202 [PMID: 26953178]
  31. Cancer Res. 2013 Jan 15;73(2):473-7 [PMID: 23316035]
  32. Cancer Sci. 2012 May;103(5):837-45 [PMID: 22320679]
  33. EMBO J. 2004 Oct 13;23(20):4051-60 [PMID: 15372072]
  34. Cell Death Dis. 2019 Nov 6;10(11):843 [PMID: 31695022]
  35. J Cell Physiol. 2018 May;233(5):3729-3744 [PMID: 28771724]
  36. J Clin Oncol. 2008 Mar 10;26(8):1364-70 [PMID: 18323559]
  37. J Cell Physiol. 2018 Sep;233(9):6583-6590 [PMID: 29115664]

Grants

  1. 82102105/National Natural Science Foundation of China
  2. LQ22H160017/National Science Foundation of Zhejiang Province
Journal Article

Word Cloud

Created with Highcharts 10.0.0modelprognosticmethylationmiRNAHCCpatientshepatocellularcarcinoma0leveldevelopmiRNAsmiR-223prognosisbasedUsinggenesleastabsoluteshrinkageselectionoperatormultivariateCoxregressionanalysesperformedOneselectedverificationdevelopedusingeightareascurvepredictingoverallsurvival13 and5 years7581 and81foundhypomethylated160tissuesassociatedBarcelonaClinicLiverCancer stageslevelscapabilitypartiallyforecastConstructiongenome-wideanalysis

Similar Articles

Cited By